Protez Pharmaceuticals
Protez Pharmaceuticals develops new antibiotics to combat the growing problem of drug resistance, as well as agents that improve the efficacy of current antibiotics. The Company's focus is difficult-to-treat hospital-based infections. In the United States alone, over eight million people are hospitalized with bacterial infections each year, accounting for greater then 90 million days of therapy. Many of these infections are serious and extremely difficult to threat. Additionally, of great concern to health care professionals is the fact that life-threatening microbes have developed resistant strains that no longer respond to any of the available antibiotics. Easton participated in the latest round of financing with BioAdvance Ventures, Birchmere Ventures, L Capital Partners and S.R. One., among others.